Compare DDD & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDD | ASMB |
|---|---|---|
| Founded | 1986 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 373.9M | 414.7M |
| IPO Year | N/A | 2010 |
| Metric | DDD | ASMB |
|---|---|---|
| Price | $2.27 | $27.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.75 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 3.9M | 98.0K |
| Earning Date | 03-25-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $391,651,000.00 | $37,191,000.00 |
| Revenue This Year | N/A | $33.33 |
| Revenue Next Year | $1.31 | N/A |
| P/E Ratio | $21.77 | ★ N/A |
| Revenue Growth | N/A | ★ 31.30 |
| 52 Week Low | $1.32 | $7.75 |
| 52 Week High | $4.85 | $39.71 |
| Indicator | DDD | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 49.33 | 44.62 |
| Support Level | $1.97 | $25.14 |
| Resistance Level | $2.35 | $27.48 |
| Average True Range (ATR) | 0.17 | 1.71 |
| MACD | -0.04 | 0.20 |
| Stochastic Oscillator | 30.98 | 45.45 |
3D Systems Corp provides comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, advanced manufacturing and applications engineering. The company's segments include Healthcare Solutions and Industrial Solutions. It generates maximum revenue from the Industrial segment. It conducts business through various offices and facilities located throughout the Americas, EMEA, and APAC; generating a vast majority of revenues from the Americas.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.